Adeno-Associated Virus (AAV) Versus Immune Response
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Decades ago, Friedmann and Roblin postulated several barriers to gene therapy, including tissue targeting, delivery across the blood–brain barrier (BBB), and host immune responses. These issues remain pertinent till today. Since then, several advances have been made in elucidating structures of adeno-associated virus (AAV) serotypes, antibody epitopes, and ways to modify antibody-binding sites. AAVs capsid has also been engineered to re-direct tissue tropism, reduce ubiquitination, and promote passage across the BBB. Furthermore, the use of high(er) dose recombinant AAV (rAAV) has been accompanied by a better understanding of immune responses in both experimental animals and early clinical trials, and novel work is being performed to modulate the immune response. While the immune responses to rAAV remains a major challenge in translating experimental drugs to approved medicine, and will likely require more than a single solution, we now better understand the hurdles to formulate and test experimental solutions to surmount them.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Endosomal TLR9, present in Kupffer cells or DCs, particularly binds to unmethylated CpG dinucleotides in the double-stranded DNA (dsDNA) vector genomes [36].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304 · cited 2×
“With the exception of TLR3, all other mammalian TLRs signal through the signaling adaptor myeloid differentiation primary response gene 88 (MyD88), and this cascade leads to phosphorylation and degradation of Inhibitor of NF kappa B (IκB), thereby releasing inhibition on NF-κB and allowing it to translocate to the nuc…”
BackgroundToll-Like Receptor Signaling Pathways
Kawasaki, T., & Kawai, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00461 · Cited by 3,233
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 2×
“Subsequently, it was determined to be an AAV capsid-specific CD8+ cytotoxic T cell response that likely led to the decline of factor IX expression, while other patients had preexisting humoral antibodies [22].”
BackgroundAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970 · cited 1×
“When tested against two IVIG neutralization preparations, AAV-LK03 demonstrated significant levels of resistance, which is somewhat surprising considering the amount of cross-reactivity between AAV serotypes in the human population [21], and AAV2 and AAV3b in particular [20].”
BackgroundDNA shuffling of a family of genes from diverse species accelerates directed evolution
Crameri, A., Raillard, S.-A., Bermudez, E., & Stemmer, W. P. C. (1998) · Nature · doi:10.1038/34663 · Cited by 825 · cited 5×
“Coupling this reassembly with error prone PCR further increased the diversity of resulting chimeric capsids.”
BackgroundInfluentialFriedmann, T., & Roblin, R. (1972) · Science · doi:10.1126/science.175.4025.949 · Cited by 815 · cited 1×
“Friedmann and Roblin postulated several barriers to gene therapy decade ago [1].”
BackgroundWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 1×
“However, natural infection studies demonstrated existing wt AAV in human samples, and the presence of neutralizing antibodies in healthy subjects throughout the world [18,19] or in specific gene therapy target populations [20].”
BackgroundMapping of the Inducible IκB Phosphorylation Sites That Signal Its Ubiquitination and Degradation†
Didonato, J., Mercurio, F., Rosette, C., Wu-Li, J., Suyang, H., Ghosh, S., & Karin, M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.4.1295 · Cited by 707 · cited 1×
“In the case of I Kappa B degradation, serine phosphorylation is the key modification leading to ubiquitination [41].”
BackgroundGrimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A. (2008) · Journal of Virology · doi:10.1128/jvi.00254-08 · Cited by 696
Dystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655 · cited 3×
“This was the case in an AAV DMD clinical trial, in which patient 5 developed CD8+ T cells against a deleted region of the endogenous mutant dystrophin that was present on the therapeutic protein [30].”
BackgroundMethodInfluentialSelf-citationThe atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612 · cited 3×
“The virion consists of 60 capsid subunits that form T = 1 icosahedral-symmetry composed of Vp1, Vp2, and Vp3 at a 1:1:10 ratio, respectively [4].”
BackgroundMethodInfluentialDirected evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538 · cited 2×
“Point mutations that resulted in the greatest resistance to human sera, screened for AAV neutralization ability, were R459K and N551D, resulting in 10-fold greater resistance [53], and E12A, K258N, T567S, N587I, and T716A, resulting in 100-fold greater resistance [52].”
BackgroundMethodGenetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. (1999) · Nature Medicine · doi:10.1038/12491 · Cited by 405 · cited 1×
“[34] used guided insertional mutagenesis of AAV2 to insert a 14-AA peptide into six-putative loop regions, using the canine parvovirus crystal structure as a guide.”
MethodGirod, A., Wobus, C. E., Zádori, Z., Ried, M., Leike, K., Tijssen, P., Kleinschmidt, J. A., & Hallek, M. (2002) · Journal of General Virology · doi:10.1099/0022-1317-83-5-973 · Cited by 354 · cited 1×
“More than 530 carboxyl terminal amino acid residues (AAs) overlap among the Cap proteins, with Vp1 and Vp2 sharing more than 60 overlapping AA, and Vp1 possessing a 137-AA unique N-terminus that contains a parvovirus genus-conserved phospholipase A2 domain required for endosome escape and efficient transduction of inf…”
BackgroundAdeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05107-11 · Cited by 345 · cited 1×
“However, natural infection studies demonstrated existing wt AAV in human samples, and the presence of neutralizing antibodies in healthy subjects throughout the world [18,19] or in specific gene therapy target populations [20].”
BackgroundZhu, J., Huang, X., & Yang, Y. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37607 · Cited by 330 · cited 2×
“revealed that innate immune recognition of AAV2 by mouse or human plasmacytoid dendritic cells (pDCs) was mediated by TLR9, dependent on MyD88 signaling, and was independent of the form of transgene or capsid serotype [13].”
BackgroundPost-proteasomal antigen processing for major histocompatibility complex class I presentation
Rock, K. L., York, I. A., & Goldberg, A. L. (2004) · Nature Immunology · doi:10.1038/ni1089 · Cited by 273 · cited 3×
“Proteasomes degrade ubiquitinated proteins into small peptide fragments that are, for the most part, too small to be taken into the endoplasmic reticulum (ER) by the transporter associated with antigen processing (TAP) [42].”
BackgroundLi, W., Asokan, A., Wu, Z., Van Dyke, T., DiPrimio, N., Johnson, J. S., Govindaswamy, L., Agbandje-McKenna, M., Leichtle, S., Eugene Redmond Jr, D., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.100 · Cited by 261 · cited 2×
“[40] used AAV1-6, 8, and 9 to generate the chimeric vector 1829.”
BackgroundMethodSelf-citationStructure of Adeno-Associated Virus Serotype 8, a Gene Therapy Vector
Nam, H.-J., Lane, M. D., Padron, E., Gurda, B., McKenna, R., Kohlbrenner, E., Aslanidi, G., Byrne, B., Muzyczka, N., Zolotukhin, S., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01304-07 · Cited by 255
CpG-depleted adeno-associated virus vectors evade immune detection
Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254 · cited 1×
“The wt transgene lost expression over 30 days while the CpG depleted transgene-maintained expression for >90 days [14] (Figure 1).”
BackgroundSelf-citationMendell, J. R., Rodino‐Klapac, L. R., Rosales, X. Q., Coley, B. D., Galloway, G., Lewis, S., Malik, V., Shilling, C., Byrne, B. J., Conlon, T., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22251 · Cited by 248 · cited 1×
“Six months post administration, two out of three patients expressed the delivered transgene, while the third patient exhibited detectable humoral and cellular immunity and showed no expression [33].”
BackgroundMartino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246 · cited 1×
“In mice, a difference in AAV genome configuration may influence the innate response; self-complimentary AAV genomes increased the innate immune response to transgene, whereas the response to single stranded vectors was less severe [16].”
BackgroundZhong, L., Li, B., Jayandharan, G., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R. W., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., et al. (2008) · Virology · doi:10.1016/j.virol.2008.08.027 · Cited by 232 · cited 2×
“In a logical series of experiments [26,43], Zhong et al.”
BackgroundLi, C., Narkbunnam, N., Samulski, R. J., Asokan, A., Hu, G., Jacobson, L. J., Manco-Johnson, M. J., Monahan, P. E., & The Joint Outcome Study Investigators (2012) · Gene Therapy · doi:10.1038/gt.2011.90 · Cited by 225 · cited 2×
“When tested against two IVIG neutralization preparations, AAV-LK03 demonstrated significant levels of resistance, which is somewhat surprising considering the amount of cross-reactivity between AAV serotypes in the human population [21], and AAV2 and AAV3b in particular [20].”
BackgroundSelf-citationStructural insight into the unique properties of adeno-associated virus serotype 9
DiMattia, M. A., Nam, H.-J., Van Vliet, K., Mitchell, M., Bennett, A., Gurda, B. L., McKenna, R., Olson, N. H., Sinkovits, R. S., Potter, M., et al. (2012) · Journal of Virology · doi:10.1128/jvi.07232-11 · Cited by 219
Hösel, M., Broxtermann, M., Janicki, H., Esser, K., Arzberger, S., Hartmann, P., Gillen, S., Kleeff, J., Stabenow, D., Odenthal, M., et al. (2012) · Hepatology · doi:10.1002/hep.24625 · Cited by 219 · cited 1×
“Finally, a study reported that primary human liver cells can mount an innate immune response against AAV2 and AAV8 capsid in vitro via TLR2 [17].”
BackgroundLimb‐girdle muscular dystrophy type 2D gene therapy restores α‐sarcoglycan and associated proteins
Mendell, J. R., Rodino‐Klapac, L. R., Rosales‐Quintero, X., Kota, J., Coley, B. D., Galloway, G., Craenen, J. M., Lewis, S., Malik, V., Shilling, C., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21732 · Cited by 214
Tse, L. V., Klinc, K. A., Madigan, V. J., Castellanos Rivera, R. M., Wells, L. F., Havlik, L. P., Smith, J. K., Agbandje-McKenna, M., & Asokan, A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704766114 · Cited by 210 · cited 3×
“Illumina sequencing of the unselected library showed minimal bias, while the selected library showed increased lead selection [51].”
BackgroundMethodInfluentialLochrie, M. A., Tatsuno, G. P., Christie, B., McDonnell, J. W., Zhou, S., Surosky, R., Pierce, G. F., & Colosi, P. (2006) · Journal of Virology · doi:10.1128/jvi.80.2.821-834.2006 · Cited by 201 · cited 3×
“advantage of this blueprint to examine mutations in 64 positions that were all surface displayed [36].”
BackgroundInfluentialDNA Shuffling of Adeno-associated Virus Yields Functionally Diverse Viral Progeny
Koerber, J. T., Jang, J.-H., & Schaffer, D. V. (2008) · Molecular Therapy · doi:10.1038/mt.2008.167 · Cited by 181
The structure of porcine parvovirus: comparison with related viruses
Simpson, A. A., Hébert, B., Sullivan, G. M., Parrish, C. R., Zádori, Z., Tijssen, P., & Rossmann, M. G. (2002) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.5319 · Cited by 160
Zhong, L., Zhao, W., Wu, J., Li, B., Zolotukhin, S., Govindasamy, L., Agbandje-McKenna, M., & Srivastava, A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300170 · Cited by 146 · cited 2×
“In a logical series of experiments [26,43], Zhong et al.”
BackgroundStructural Characterization of the Dual Glycan Binding Adeno-Associated Virus Serotype 6
Ng, R., Govindasamy, L., Gurda, B. L., McKenna, R., Kozyreva, O. G., Samulski, R. J., Parent, K. N., Baker, T. S., & Agbandje-McKenna, M. (2010) · Journal of Virology · doi:10.1128/jvi.01235-10 · Cited by 143
Self-citationInsertional Mutagenesis of AAV2 Capsid and the Production of Recombinant Virus
Rabinowitz, J. E., Xiao, W., & Samulski, R. J. (1999) · Virology · doi:10.1006/viro.1999.0045 · Cited by 136 · cited 1×
“[35] used random insertional mutagenesis, placing four to five AAs into 22 sites, spanning all three capsid regions.”
MethodSelf-citationCombinatorial engineering of a gene therapy vector: directed evolution of adeno‐associated virus
Perabo, L., Endell, J., King, S., Lux, K., Goldnau, D., Hallek, M., & Büning, H. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.849 · Cited by 136
Erratum: Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M. U., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. J. (1999) · Nature Medicine · doi:10.1038/71021 · Cited by 136
Crystal Structure of the SF3 Helicase from Adeno-Associated Virus Type 2
James, J. A., Escalante, C. R., Yoon-Robarts, M., Edwards, T. A., Linden, R. M., & Aggarwal, A. K. (2003) · Structure · doi:10.1016/s0969-2126(03)00152-7 · Cited by 135
Capsid antibodies to different adeno-associated virus serotypes bind common regions
Gurda, B. L., DiMattia, M. A., Miller, E. B., Bennett, A., McKenna, R., Weichert, W. S., Nelson, C. D., Chen, W.-J., Muzyczka, N., Olson, N. H., et al. (2013) · Journal of Virology · doi:10.1128/jvi.00622-13 · Cited by 127 · cited 1×
“However, for AAV5 the antigenic footprint flanks the 2/5-fold wall [49,50].”
BackgroundSelf-citationMonahan, P. E., Lothrop, C. D., Sun, J., Hirsch, M. L., Kafri, T., Kantor, B., Sarkar, R., Tillson, D. M., Elia, J. R., & Samulski, R. J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.170 · Cited by 125 · cited 1×
“Proteasome inhibitors have been shown to increase transduction in vitro and reduce the presentation of capsid peptide fragments on MHC class I molecules [24,25].”
BackgroundSelf-citationFinn, J. D., Hui, D., Downey, H. D., Dunn, D., Pien, G. C., Mingozzi, F., Zhou, S., & High, K. A. (2010) · Molecular Therapy · doi:10.1038/mt.2009.257 · Cited by 115 · cited 1×
“Proteasome inhibitors have been shown to increase transduction in vitro and reduce the presentation of capsid peptide fragments on MHC class I molecules [24,25].”
BackgroundStructure of Adeno-Associated Virus Serotype 5
Walters, R. W., Agbandje-McKenna, M., Bowman, V. D., Moninger, T. O., Olson, N. H., Seiler, M., Chiorini, J. A., Baker, T. S., & Zabner, J. (2004) · Journal of Virology · doi:10.1128/jvi.78.7.3361-3371.2004 · Cited by 114
Structure of Adeno-Associated Virus Type 4
Padron, E., Bowman, V., Kaludov, N., Govindasamy, L., Levy, H., Nick, P., McKenna, R., Muzyczka, N., Chiorini, J. A., Baker, T. S., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.8.5047-5058.2005 · Cited by 108
Mays, L. E., Vandenberghe, L. H., Xiao, R., Bell, P., Nam, H.-J., Agbandje-McKenna, M., & Wilson, J. M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803965 · Cited by 99 · cited 1×
“33 injection in mice results in a robust T cell response to both the capsid and the transgene product, this is unlike the T cell response to other AAV serotypes in mice [15].”
BackgroundMapping a Neutralizing Epitope onto the Capsid of Adeno-Associated Virus Serotype 8
Gurda, B. L., Raupp, C., Popa-Wagner, R., Naumer, M., Olson, N. H., Ng, R., McKenna, R., Baker, T. S., Kleinschmidt, J. A., & Agbandje-McKenna, M. (2012) · Journal of Virology · doi:10.1128/jvi.00218-12 · Cited by 93
Gabriel, N., Hareendran, S., Sen, D., Gadkari, R. A., Sudha, G., Selot, R., Hussain, M., Dhaksnamoorthy, R., Samuel, R., Srinivasan, N., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.194 · Cited by 90 · cited 2×
“These mutations were extended to other targets of phosphorylation (serine, threonine, and lysine residues) and to other serotypes (AAV6 and AAV8), and examined in large animal models [27,44].”
BackgroundWikoff, W. R., Wang, G., Parrish, C. R., Cheng, R. H., Strassheim, M. L., Baker, T. S., & Rossmann, M. G. (1994) · Structure · doi:10.1016/s0969-2126(00)00062-9 · Cited by 88 · cited 1×
“Early attempts to map neutralizing antibodies complexed to parvovirus capsids by CryoEM were successful at mapping antigenic AAs, with the help of neutralization escape mutants for verification [47].”
BackgroundAkache, B., Grimm, D., Shen, X., Fuess, S., Yant, S. R., Glazer, D. S., Park, J., & Kay, M. A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300053 · Cited by 85
AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes
Hui, D. J., Edmonson, S. C., Podsakoff, G. M., Pien, G. C., Ivanciu, L., Camire, R. M., Ertl, H., Mingozzi, F., High, K. A., & Basner-Tschakarjan, E. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.29 · Cited by 84 · cited 2×
“However, after restimulation with AAV peptides, 20 of 32 patient splenocytes were positive in IFN-γ ELISPOT assay [28].”
BackgroundMethodKumar, S. R. P., Hoffman, B. E., Terhorst, C., de Jong, Y. P., & Herzog, R. W. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.014 · Cited by 83
Tseng, Y.-S., Gurda, B. L., Chipman, P., McKenna, R., Afione, S., Chiorini, J. A., Muzyczka, N., Olson, N. H., Baker, T. S., Kleinschmidt, J., et al. (2015) · Journal of Virology · doi:10.1128/jvi.02710-14 · Cited by 70 · cited 1×
“For example, the AAV1 binding footprint of MAb 4E4 contains residues from variable regions (VR) III–IX, occluding 83 residues, but contacts residues 456-AQNK-459 and 492-TKDNNN-498 from VR IV and V, respectively [48].”
BackgroundAdeno-associated virus capsid antigen presentation is dependent on endosomal escape
Li, C., He, Y., Nicolson, S., Hirsch, M., Weinberg, M. S., Zhang, P., Kafri, T., & Samulski, R. J. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66611 · Cited by 61 · cited 3×
“Proteasomes degrade ubiquitinated proteins into small peptide fragments that are, for the most part, too small to be taken into the endoplasmic reticulum (ER) by the transporter associated with antigen processing (TAP) [42].”
BackgroundSelf-citationLi, B., Ma, W., Ling, C., Vliet, K. V., Huang, L.-Y., Agbandje‐McKenna, M., Srivastava, A., & Aslanidi, G. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.115 · Cited by 35
Hakim, C. H., Yue, Y., Shin, J., Williams, R. R., Zhang, K., Smith, B. F., & Duan, D. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.2 · Cited by 33
Cited by
Strategies for delivering therapeutics across the blood–brain barrier
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138
CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
Wang, D., Zhang, F., & Gao, G. (2020) · Cell · doi:10.1016/j.cell.2020.03.023 · Cited by 527
“These topics were discussed in depth in recent reviews (Colella et al., 2017; Domenger and Grimm, 2019; Rabinowitz et al., 2019; Verdera et al., 2020; Wang et al., 2019).”
AAV vectors: The Rubik’s cube of human gene therapy
Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.09.015 · Cited by 360
Self-citationViral vector‐based gene therapies in the clinic
Zhao, Z., Anselmo, A. C., & Mitragotri, S. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10258 · Cited by 269
Exosome-mediated delivery of gene vectors for gene therapy
Duan, L., Xu, L., Xu, X., Qin, Z., Zhou, X., Xiao, Y., Liang, Y., & Xia, J. (2021) · Nanoscale · doi:10.1039/d0nr07622h · Cited by 238
Metadata
- Authors
- Rabinowitz, J., Chan, Y. K., & Samulski, R. J.
- Affiliations
- Pfizer (United States) (US)
- Harvard University (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Rabinowitz, Joseph
- Chan, Ying Kai
- Samulski, Richard Jude
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2019-01-25
- Volume
- 11
- Issue
- 2
- Pages
- 102
- ISSN
- 1999-4915 (ISSN-L)
- PMC
- PMC6409805
- OpenAlex
- W2911711918
- Cited by
- 122
- References
- 54
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 14 · 2023: 16 · 2022: 17 · 2021: 29 · 2020: 24 · 2019: 6
- FWCI
- 2.52
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Viruses (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Heart, Lung, and Blood Institute (P01HL112761)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus, recombinant adeno-associated virus, gene therapy, immune response, AAV serotypes, capsid engineering, antibody epitopes, tissue tropism, blood-brain barrier, ubiquitination, immunomodulation, clinical translation
- MeSH terms
- Host Microbial Interactions, Dependovirus, Animals, Clinical Trials as Topic, Genetic Vectors, Humans, Immunity, Innate, Parvoviridae Infections, Genetic Therapy, Capsid Proteins, Mice, Adaptive Immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.